Page 87 - 2021年15期
P. 87

参考文献                                                    病[J].肝脏,2020,25(8):894-896.
        [ 1 ]  徐文静,范江霖. PPARα与 FXR 通路在非酒精性脂肪肝              [14]  ZHANG Y F,YUAN Z Q,SONG D G,et al. Effects of
             病中的交互作用[J]. 生命的化学,2020,40(9):1500-                 cannabinoid receptor 1(brain)on lipid accumulation by
             1506.                                              transcriptional control of CPT1A and CPT1B[J]. Anim
        [ 2 ]  KERSTEN S,STIENSTRA R. The role and regulation of  Genet,2014,45(1):38-47.
             the peroxisome proliferator activated receptor alpha in hu-  [15]  YAHAGHI L,YAGHMAEI P,HAYATI-ROODBARI N,
             man liver[J]. Biochimie,2017,136:75-84.            et al. Betanin effect on PPAR-alpha and SREBP-1c expres-
        [ 3 ]  THANAPIROM K,TSOCHATZIS E A. Non-alcoholic fat-  sion in NMRI mice model of steatohepatitis with fibro-
             ty liver disease(NAFLD)and the quest for effective treat-  sis[J]. Physiol Int,2020,107(1):67-81.
             ments[J]. Hepatobiliary Surg Nutr,2019,8(1):77-79.  [16]  张中乐,沈红艺,倪红梅,等. SIRT1在非酒精性脂肪性肝
        [ 4 ]  李生鹏,王全楚.非酒精性脂肪性肝病的流行病学进                          病脂质代谢机制中的作用研究进展[J].中西医结合肝病
             展[J].胃肠病学和肝病学杂志,2017,26(10):1085-1087.             杂志,2020,30(5):472-474.
        [ 5 ]  许炎煌,范建高.非酒精性脂肪性肝病治疗药物研究进                    [17]  冯秋琪,任国艳,乔香君,等.脂肪肝细胞模型的研究进
             展[J].上海医药,2020,41(19):3-6.                         展[J].中国细胞生物学学报,2020,42(12):2256-2265.
        [ 6 ]  NASCIMBENI F,PELLEGRINI E,LUGARI S,et al.   [18]  QU C,TANG L,ZHU Y. Effect of fenofibrate on the secre-
             Statins and nonalcoholic fatty liver disease in the era of  tion of endothelium-derived contracting factors in hyper-
             precision medicine:more friends than foes[J]. Atheroscle-  tensive rats[J]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao,
             rosis,2019,284:66-74.                              2012,34(3):239-243.
        [ 7 ]  钱坤,刘亚云,张艳,等.中药抗非酒精性脂肪肝病分子机                  [19]  刘晶晶.化瘀祛痰方对FFA诱导HepG2细胞脂质沉积的
             制的研究进展[J].中草药,2020,51(19):5083-5092.               影响及机制研究[D].沈阳:辽宁中医药大学,2018.
        [ 8 ]  王洪伟,盛邦跃,林超.桑白皮药理作用研究进展[J].中医                [20]  芮法娟,杨红丽,吕卓珍,等.非酒精性脂肪性肝病的流行
             学报,2019,34(6):1183-1187.                           病学研究进展[J].山东医药,2020,60(31):89-92.
        [ 9 ]  候宝林,施洋,赵俊芳,等.桑白皮化学成分及药理作用研                  [21]  刘勤,牛春燕.由“二次打击”到“多重打击”:发病机制的
             究进展[J].辽宁中医杂志,2020,47(8):212-214.                  演变带给非酒精性脂肪性肝病的治疗启示[J].世界华人
        [10]  GUO H,XU Y,HUANG W,et al. Kuwanon G preserves     消化杂志,2019,27(19):1171-1178.
             LPS-induced disruption of gut epithelial barrier in vi-  [22]  JIAO H L,YE P,ZHAO B L. Protective effects of green
             tro[J]. Molecules,2016,21(11):1597.                tea polyphenols on human HepG2 cells against oxidative
        [11]  ANN J Y,EO H,LIM Y. Mulberry leaves(Morus alba    damage of fenofibrate[J]. Free Radic Biol Med,2003,35
             L.)ameliorate obesity-induced hepatic lipogenesis,fibro-  (9):1121-1128.
             sis,and oxidative stress in high-fat diet-fed mice[J].  [23]  路然,洪天配.脂质代谢紊乱导致非酒精性脂肪性肝病的
             Genes Nutr,2015,10(6):46.                          发病机制[J].临床肝胆病杂志,2015,31(7):1050-1054.
        [12]  段志涛,高英,周刚.桑白皮药材的质量标准研究[J].中药                                (收稿日期:2021-04-16  修回日期:2021-06-05)
             材,2013,36(4):553-557.                                                              (编辑:唐晓莲)
        [13]  徐文静. PPARα参与脂代谢通路与非酒精性脂肪性肝








                  《中国药房》杂志——中国科技核心期刊,欢迎投稿、订阅














        中国药房    2021年第32卷第15期                                             China Pharmacy 2021 Vol. 32 No. 15  ·1873 ·
   82   83   84   85   86   87   88   89   90   91   92